- ByReuters-
- 2
By Blake Brittain and Nichola Groom NORFOLK, Virginia, Jan 16 (Reuters) - A federal judge on Friday cleared U.S. power company...
Last | High | Low | |||||
|---|---|---|---|---|---|---|---|
| 323.2 | 326.0 | 320.9 | -0.3 | -0.09% | 1.03M | ||
| 857.0 | 861.8 | 854.2 | -4.4 | -0.51% | 140.83K | ||
| 1,769.5 | 1,793.5 | 1,762.5 | -8.5 | -0.48% | 408.19K | ||
| 388.9 | 391.3 | 374.1 | +23.7 | +6.49% | 13.94M | ||
| 14,895 | 14,955 | 14,690 | -60 | -0.40% | 16.32K | ||
| 418.3 | 421.0 | 414.0 | -3.8 | -0.90% | 580.76K | ||
| 14,880 | 14,950 | 14,700 | -70 | -0.47% | 4.03K | ||
| 796.5 | 805.0 | 792.5 | +3.0 | +0.38% | 123.18K | ||
| 2,185.0 | 2,209.0 | 2,160.0 | +21.0 | +0.97% | 104.3K | ||
| 519.0 | 523.5 | 515.0 | +4.0 | +0.78% | 195.69K | ||
| 184.7 | 185.5 | 180.5 | -1.4 | -0.75% | 9.73M | ||
| 233.0 | 236.2 | 229.2 | +1.8 | +0.78% | 413.09K | ||
| 161.7 | 162.4 | 160.5 | -0.1 | -0.06% | 529.78K | ||
| 577.4 | 579.8 | 572.8 | +0.6 | +0.10% | 208.94K | ||
| 944.0 | 955.5 | 938.0 | -4.0 | -0.42% | 105.24K | ||
| 550.0 | 556.4 | 536.0 | +4.2 | +0.77% | 485.5K | ||
| 209 | 213 | 208 | -2 | -0.95% | 393.54K | ||
| 419.50 | 420.50 | 406.90 | +12.20 | +3.00% | 266.03K | ||
| 237.60 | 239.60 | 236.20 | -1.40 | -0.59% | 327.76K | ||
| 135.50 | 135.65 | 131.00 | +4.45 | +3.40% | 2.64M |
By Blake Brittain and Nichola Groom NORFOLK, Virginia, Jan 16 (Reuters) - A federal judge on Friday cleared U.S. power company...
By Bhanvi Satija and Maggie Fick LONDON, Jan 16 (Reuters) - Novo Nordisk’s Wegovy weight-loss pill has made an encouraging start...
By Niket Nishant and Avinash P Jan 16 (Reuters) - European shares were subdued on Friday, limited by weakness in luxury and...
Novo Nordisk (NVO) shares surged on Monday, November 10, 2025, climbing to $46.18 as of 6:47 AM EST after closing at $45.68 the...
We last wrote about Novo Nordisk A/S Class B (CSE:NOVOb) less than six months ago, on February 20th. The stock was trading just...
Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk (NYSE:NVO) A/S, Lars Fruergaard...
No Earning Reports have been scheduled